Cargando…
Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes
Arsenic trioxide (As(2)O(3)) has recently become one of the most effective drugs for treatment of patient with acute promyelocytic leukemia (APL), and its molecular mechanism has also been largely investigated. However, it has been reported that As(2)O(3) resistant patients are frequently found in r...
Autores principales: | Jiang, Yu Han, Chen, Ye Jia, Wang, Chao, Lan, Yong Fei, Yang, Chang, Wang, Qian Qian, Hussain, Liaqat, Maimaitiying, Yasen, Islam, Khairul, Naranmandura, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343784/ https://www.ncbi.nlm.nih.gov/pubmed/28125064 http://dx.doi.org/10.3390/ijms18020247 |
Ejemplares similares
-
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation
por: Wang, Qian Qian, et al.
Publicado: (2015) -
Phenylarsine oxide inhibits the accumulation of lipid droplets in macrophages
por: Xie, Yuyu, et al.
Publicado: (2022) -
Metabolism, toxicity and anticancer activities of arsenic compounds
por: Khairul, Islam, et al.
Publicado: (2017) -
Defining cutaneous molecular pathobiology of arsenicals using phenylarsine oxide as a prototype
por: Srivastava, Ritesh K., et al.
Publicado: (2016) -
Shifting the Specificity of E. coli Biosensor from Inorganic Arsenic to Phenylarsine Oxide through Genetic Engineering
por: Kim, Hyojin, et al.
Publicado: (2020)